InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026)
InMed Pharmaceuticals (INM) reported Interest & Investment Income of $47770.0 for Q1 2026, up 188.38% on a YoY basis from $16565.0 in Q1 2025, and down 35.77% quarter-over-quarter from $74379.0 in Q4 2025.
InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Interest & Investment Income for 8 years, with the latest figure at $47770.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 188.38% year-over-year to $47770.0; the trailing twelve-month figure through Mar 2026 stood at $267601.0 (up 28.76% YoY), and the FY2025 full-year result was $155882.0, down 70.47% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $47770.0, down from $74379.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $166760.0 in Q4 2023, with the low at $16565.0 in Q1 2025.
- Historically, Interest & Investment Income has averaged $85694.2 across 5 years, with a median of $74379.0 in 2025.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1310.0% — and 2025, when it sank 86.36%.
- InMed Pharmaceuticals' Interest & Investment Income stood at $115797.0 in 2022, then soared by 44.01% to $166760.0 in 2023, then plunged by 81.69% to $30536.0 in 2024, then jumped by 143.58% to $74379.0 in 2025, then plunged by 35.77% to $47770.0 in 2026.
- The last three Interest & Investment Income figures came in at $47770.0 (Q1 2026), $74379.0 (Q4 2025), and $93765.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 41.80 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 28.10 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 8.54 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 4.97 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | InMed Pharmaceuticals | 5.94 Mn | 696,491.41 | - | 47,770.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,770.00 |
| Dec 31, 2025 | 74,379.00 |
| Sep 30, 2025 | 93,765.00 |
| Jun 30, 2025 | 51,687.00 |
| Mar 31, 2025 | 16,565.00 |
| Dec 31, 2024 | 30,536.00 |
| Sep 30, 2024 | 57,094.00 |
| Jun 30, 2024 | 103,640.00 |
| Mar 31, 2024 | 121,458.00 |
| Dec 31, 2023 | 166,760.00 |
| Sep 30, 2023 | 136,043.00 |
| Jun 30, 2023 | 148,559.00 |
| Mar 31, 2023 | 155,497.00 |
| Dec 31, 2022 | 115,797.00 |
| Sep 30, 2022 | 72,587.00 |
| Jun 30, 2022 | 33,701.00 |
| Mar 31, 2022 | 30,964.00 |
| Dec 31, 2021 | 26,277.00 |
| Sep 30, 2021 | 5,148.00 |
| Jun 30, 2021 | 4,825.00 |